News Conference News EuroPCR 2024 POLMIDES: Hybrid Revascularization Bests CABG For 10-Year Survival Yael L. Maxwell May 22, 2024
News Conference News EuroPCR 2024 PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3 Yael L. Maxwell May 17, 2024
News Conference News EuroPCR 2024 TAVI, Surgery Look Similar Long-term Across Risk Spectrum: Meta-analysis Michael O'Riordan May 16, 2024
News Conference News EuroPCR 2024 Young, Low-risk Patients Fare Well With TAVI, but Beware the Bicuspids Michael O'Riordan May 15, 2024
Presentation EuroPCR 2024 Long-term outcomes of transcatheter aortic valve vs. surgical aortic valve replacement Presenter: Eliano Navarese May 15, 2024
Presentation EuroPCR 2024 Is coronary artery bypass surgery cost-effective compared with contemporary PCI? A FAME 3 analysis Presenter: Frederik Zimmermann May 15, 2024
Presentation EuroPCR 2024 Hybrid coronary revascularisation–10-year clinical outcomes of the prospective randomised study. Presenter: Mateusz Tajstra May 15, 2024
Presentation EuroPCR 2024 First TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis - results from NOTION-2 Presenter: Ole De Backer May 15, 2024
News Conference News EuroPCR 2024 NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD Michael O'Riordan May 14, 2024
Presentation EuroPCR 2024 Short Methodology Insight - NOTION-2 Presenter: Davide Capodanno May 14, 2024